Short Interest in CureVac (NASDAQ:CVAC) Declines By 6.4%

CureVac (NASDAQ:CVAC - Get Free Report) was the target of a significant drop in short interest in December. As of December 15th, there was short interest totalling 3,940,000 shares, a drop of 6.4% from the November 30th total of 4,210,000 shares. Approximately 4.2% of the company's shares are short sold. Based on an average trading volume of 508,300 shares, the short-interest ratio is presently 7.8 days.

Analyst Ratings Changes

Separately, JMP Securities reaffirmed a "market outperform" rating and set a $16.00 target price on shares of CureVac in a research note on Monday, September 16th.

Hedge Funds Weigh In On CureVac

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp acquired a new position in CureVac in the 2nd quarter valued at $54,000. Signaturefd LLC grew its position in shares of CureVac by 232.0% in the second quarter. Signaturefd LLC now owns 22,043 shares of the company's stock valued at $75,000 after purchasing an additional 15,403 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its stake in shares of CureVac by 99.8% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 44,044 shares of the company's stock worth $147,000 after purchasing an additional 21,999 shares during the period. XTX Topco Ltd acquired a new position in shares of CureVac during the 2nd quarter worth about $108,000. Finally, Point72 Asset Management L.P. bought a new stake in CureVac during the 2nd quarter valued at approximately $8,237,000. Institutional investors and hedge funds own 17.26% of the company's stock.

CureVac Stock Up 9.3 %

Shares of NASDAQ CVAC traded up $0.29 during mid-day trading on Tuesday, reaching $3.41. The company had a trading volume of 889,839 shares, compared to its average volume of 813,002. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20. CureVac has a twelve month low of $2.21 and a twelve month high of $5.28. The stock's 50 day moving average is $2.89 and its 200-day moving average is $3.11. The stock has a market capitalization of $763.43 million, a PE ratio of 6.20, a price-to-earnings-growth ratio of 0.24 and a beta of 2.59.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.